Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-10-16
2007-10-16
Harris, Alana M. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S004000, C435S007100, C435S007210, C435S006120, C436S008000, C436S007000, C436S063000, C436S064000, C436S174000, C530S387700, C530S389700
Reexamination Certificate
active
09982286
ABSTRACT:
The invention provides methods for prognosis, diagnosis, staging and disease progression in human cancer patients related to expression levels of a variety of immunohistochemical and genetic markers associated with poor cancer prognosis, and in particular those markers related to tumor invasiveness, metastasis and spread. The invention also provides methods using a predictive index for prognosis of cancer patients for metastasis, recurrence and relapse of neoplastic disease. The methods of the invention are useful for making clinical decisions on cancer treatment, surveillance and surgical intervention.
REFERENCES:
patent: 6303324 (2001-10-01), Fruehauf
Gasparini et al. Journal of Clinical Oncology 12(3): 454-466 (1994).
Hegde Pu et al. Arch Otolaryngol Head Neck Surg 124: 80-85, 1998.
Oshika Y et al. Clinical Cancer Research 4: 1785-1788, 1998.
Salvesen HB et al. International Journal of Cancer 84: 539-543, 1999.
Salvesan et al., “Significance of Tumour-Associated Macrophages, Vascular Endothelial Growth Factor and Thrombospondin-1 Expression for Tumour Angiogenesis and Prognosis in Endometrial Carcinomas”, Int. J. Cancer, 1999, 84:539-543.
Hedge et al., “Tumor Angiogenesis and p53 Mutations”, Arch Otolaryngol Head Neck Surg, Jan. 1998, 124:80-85.
Oshika et al., “Thrombospondin 2 Gene Expression Is Correlated with Decreased Vascularity in Non-Small Cell Lung Cancer1”, Clin Can Res. Jul. 1998, 4:1785-1788.
Boring et al., “Cancer Stastistics, 1992”, CA-A Cancer Journal for Clinicians, Jan./Feb. 1992, 42:19-38.
Mansour et al., “Efficacy of Adjuvant Chemotherapy in High-Risk Node-Negative Breast Cancer”, N. Engl. Med., 1989, 320:485-490.
Osbourne et al., “Prognostic Factors for Breast Cancer: Have They Met Their Promise”, J. Clin. Oncol., May 1992, 10:679-682.
Allegra et al., “Association Between Steroid Hormone Receptor Status and Disease-Free Interval in Breast Cancer”, Cancer Treat. Rep., 1979, 63:1271-1277.
Von Rosen et al., “Prognostic Value of Nuclear DNA Content in Breast Cancer in Relation to Tumor Size, Nodal Status, and estrogen receptor content”, Breast Cancer Res. And Treat., 1989, 13:23-32.
Fisher et al., Neoplasms of the Breast, J. Natl. Cancer. Inst., 1992, 1706-1774.
Clark et al., Prediction of Relapse or Survival in Patients with Node-Negative breast Cancer by DNA Flow Cytometry, New Engl. J. Med., 1994, 320:627-633.
Fisher et al., “Prognostic Factor in NSABP Studies of Women with Node-Negative Breast Cancer”, Journal of the National Cancer Institute Monographs, 1992, 11:151-158.
Early Breast Cancer Trialists' Collaboration Group, “Systemic Treatment of Early Breast Cancer by Hormonal, Cytotoxic, or Immune Therapy”, Lancet, 1992, 339:1-15.
The Ludwig Breast Cancer Study Group, “Prolonged Disease-Free Survival After One Course of Perioperative Adjuvant Chemotherapy for Node-Negative Breast Cancer” N. Engl. Journal of Medicine, vol. 320, No. 8 pp. 491-496, 1989.
Gasparini et al., “Evaluating the Potential Usefulness of New Prognostic and Predictive Indicators in Node-Negative Breast Cancer Patients”, Jour. of the National Cancer Insti. 1993, vol. 85, No. 15 pp. 1206-1219.
Figge et al., “Image Analysis Quantitaion of Immunoreactive Retinoblastoma Protein in Human Throid Neoplasms with a Streptavidin-biotin-peroxidase Staining Technique” Amer. J. Pathol. 1991, 139:1213-1221.
Esteban et al., “Improvement of the Quantification of Estrogen and Progesterone Receptors in Paraffin-Embedded Tumors by Image Analysis”, Amer. J. Clin. Pathol., 1993, 99:32-38.
Bevilacqua et al., “Prognostic Value of Intratumoral Microvessel Density, a Measure of Tumor Angiogenesis, in node-negative breast carcinoma-results of a multiparametric study”, Breast Cancer Research and Treatment, 1995, 36:205-217.
Zabrenetzky et al., “Expression of the Extracellular Matrix Molecule Thrombospondin Inversely Correlates with Malignant Progresssion in Melanoma, Lung and Breast Carcinoma Cell Lines”, Int. J. Cancer, 1994, 59:191-195.
Iwaya et al., “Nuclear p53 Immunoreaction Associated with Poor Prognosis of Breast Cancer”, Jpn. J. Cancer Res., Jul. 1991, 82:835-840.
Gasparini et al., “Clinical Importance of the Determination of Tumor Angiogenesis in Breast Carcinoma: Much More Than a New Prognostic Tool”, Journal of Clinical Oncology, Mar. 1995, vol. 13, No. 3,765-782.
Grossfeld et al., “Thrombosphondin-1 Expression as an Independent Prognostic Indicator in Invasive Transitional Cell Carcinoma of the Bladder”, Proceedings of the American Urological Association, May 1996, vol. 155 Supplement 688A Abstract 1508.
Harris Alana M.
McDonald Boehnen Hulbert & Berghoff
Oncotech, Inc.
LandOfFree
Methods for cancer prognosis and diagnosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for cancer prognosis and diagnosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for cancer prognosis and diagnosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3903278